P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure - Fred Poordad; Stanislas Pol; Armen Asatryan; Maria Buti; David Shaw; Christophe Hézode; Franco Felizarta; Robert W. Reindollar; Stuart C. Gordon; Stephen Pianko; Michael W. Fried; David E. Bernstein; et al. (Elsevier, 2017)